MoneyThe story, in brief
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
$2B valuation. Enveda just raised $311M to push AI-discovered drugs from the lab into human trials — and it's working.
The KeyNews take
Why it matters
AI drug discovery is moving from proof-of-concept to clinical reality. Enveda's $2B valuation and clinical-stage pipeline signal that AI-designed therapeutics can clear regulatory hurdles, reshaping how biotech deploys ML for therapeutic development.
The key facts
5 to know$311M Series C funding round
$2B post-money valuation
Nature-derived compounds (AI-screened natural products, not synthetic)
Drugs in clinical trials for skin conditions and GLP-1 weight-loss rebound
AI biotech moving from discovery to clinical validation phase
Go to the source
TechCrunch AItechcrunch.com
Publisher excerpt: The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.